These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 33315863

  • 1. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A, Kusejko K, Johnson LF, Günthard HF, Riou J, Wandeler G, Egger M, Kouyos RD.
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [Abstract] [Full Text] [Related]

  • 2. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M, Butel C, Comlan AS, Konou AA, Tegueni K, Ehlan A, Lack F, Dossim S, Ayouba A, Delaporte E, Dagnra AY, Peeters M.
    AIDS; 2020 Apr 01; 34(5):783-787. PubMed ID: 31895149
    [Abstract] [Full Text] [Related]

  • 3. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D, ODYSSEY Trial Team.
    BMC Infect Dis; 2021 Jan 04; 21(1):5. PubMed ID: 33446115
    [Abstract] [Full Text] [Related]

  • 4. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
    Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, Lamorde M, Kambugu A, Reynolds H, Khoo S, Taegtmeyer M.
    BMC Public Health; 2020 Dec 07; 20(1):1883. PubMed ID: 33287795
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
    Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S, Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.
    Lancet HIV; 2018 Mar 07; 5(3):e146-e154. PubMed ID: 29174084
    [Abstract] [Full Text] [Related]

  • 6. Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age.
    Inzaule SC, Jordan MR, Cournil A, Vitoria M, Ravasi G, Cham F, Le LV, Dzangare J, Hamunime N, Mutenda N, Aghokeng A, Bissek A, Billong S, Kaleebu P, Doherty M, Bertagnolio S.
    AIDS; 2019 Sep 01; 33(11):1797-1799. PubMed ID: 31149946
    [Abstract] [Full Text] [Related]

  • 7. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.
    Ismael N, Gemusse H, Mahumane I, Laurindo O, Magul C, Baxter C, Wilkinson E, Hofstra LM, Wagar N, Bila D, Mabunda N, da Silva J, Oliveira T, Raizes E, Preiser W, Manuel P, Ramos A, Vúbil A.
    BMC Infect Dis; 2024 Jul 29; 24(1):748. PubMed ID: 39075381
    [Abstract] [Full Text] [Related]

  • 8. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA, Miller S, Childs-Kean LM.
    Ann Pharmacother; 2020 Dec 29; 54(12):1252-1259. PubMed ID: 32517480
    [Abstract] [Full Text] [Related]

  • 9. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK, Arora S, Khanna R, Raman N, Anilkumar A, Mohan C.
    Curr HIV Res; 2024 Dec 29; 22(1):31-46. PubMed ID: 38284697
    [Abstract] [Full Text] [Related]

  • 10. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
    Ndashimye E, Arts EJ.
    Int J Infect Dis; 2021 Apr 29; 105():298-303. PubMed ID: 33722682
    [Abstract] [Full Text] [Related]

  • 11. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P, Goh O, Kroon E, Colby D, Sacdalan C, Pinyakorn S, Prueksakaew P, Reiss P, Ananworanich J, Valcour V, Spudich S, Paul R, RV254/SEARCH 010 Research Team.
    AIDS Res Ther; 2020 Jan 07; 17(1):1. PubMed ID: 31907064
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dolutegravir in Mexico for special populations: A cost analysis perspective.
    Marco B, Cristina H, Cristhian R, Sigfrido R, Del Angel J, Reyes A, Isidoro P.
    AIDS Rev; 2021 Jul 01; 23(3):126-132. PubMed ID: 34198310
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, Gill J, Rabkin CS, Gange SJ, Horberg MA, Margolick J, Li J, Wong C, Willig A, Lima VD, Crane H, Thorne J, Silverberg M, Kirk G, Mathews WC, Sterling TR, Lake J, Koethe JR, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).
    J Int AIDS Soc; 2020 Apr 01; 23(4):e25484. PubMed ID: 32294337
    [Abstract] [Full Text] [Related]

  • 17. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.
    Clin Infect Dis; 2016 Mar 15; 62(6):784-91. PubMed ID: 26658053
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A, P1093 Study Team .
    J Pediatric Infect Dis Soc; 2020 Apr 30; 9(2):159-165. PubMed ID: 30951600
    [Abstract] [Full Text] [Related]

  • 19. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
    Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, Lamorde M, Kambugu A, Reynolds H, Khoo S, Taegtmeyer M.
    BMC Health Serv Res; 2020 Aug 01; 20(1):705. PubMed ID: 32738918
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
    Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, Braun DL, Vernazza P, Cavassini M, Buzzi M, Metzner KJ, Decosterd LA, Günthard HF, Schmid P, Limacher A, Egger M, Calmy A, Swiss HIV Cohort Study (SHCS).
    PLoS Med; 2020 Nov 01; 17(11):e1003421. PubMed ID: 33170863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.